Engineers designing complex hardware products now have more capital-backed intelligence at their fingertips, as Vinci, a startup building AI-native computational platforms, announced a $250.0M Series B funding round. The substantial investment comes from a syndicate including Temasek, Xora Innovation, AMD, Eclipse, Khosla Ventures, and Madrona. Vinci's platform provides Continuous Physics Reasoning, offering deterministic, solver-accurate understanding of how products will physically behave while still in the design phase, a capability already deployed in production engineering programs.
Vinci Raises $250.0M in Series B Round
Get the full Vinci company profile
Access contacts, investors, buying signals & more
From the source
AdventWe’re excited to co-lead Vinci’s $250 million Series B alongside Temasek and Xora Innovation, with participation from AMD, Eclipse, Khosla Ventures, Madrona, and other strategic industry leaders. Vinci is building an AI-native computational platform for hardware engineering.
Its core capability, Continuous Physics Reasoning, enables engineers to understand how complex products will behave while they are still being designed — helping teams explore more possibilities and make better design decisions, faster. The funding will support Vinci’s expansion across physics, engineering disciplines, and hardware industries, from semiconductors to vehicles, aircraft, and satell
Other United States companies recently funded
View all
Vitalize
Our mission: Unlock healthcare’s full capacity. Health systems still run critical operations like staffing, labor planning, and capacity on spreadsheets, phone calls, and guesswork. Vitalize is building the AI operating system for how health systems manage labor and capacity. Health systems on Vitalize dramatically reduce premium labor spend, see more patients, and allow their frontline leaders to return to the bedside. We’re trusted by leading health systems across the country and have raised more than $31M from top healthcare and technology investors, including our own customers.
$31.0M Series a
today
Telomir Pharmaceuticals, Inc.
A novel treatment uniquely and selectively binds critical metals to interrupt enzyme function, returning cellular metals like Iron, copper, and zinc to homeostasis and turning off the underlying cause of cancer development and growth. By targeting specific classes of enzymes through its metal binding properties, Telomir 1 is believed to selectively affect the key processes that drive the concentration and accumulation of iron and copper in the serum that affects diseases like hemochromatosis and cancer.
Biggest recent AI rounds
Largest funding rounds in AI on Signalbase right now.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Nuance Healthcare United States | Unknown | $19.7B | 2y ago |
| 2 |  OpenAI United States | Unknown | $13.0B |
Other recent Series b rounds
Companies that recently closed a Series b round.
| # | Company | Round | Amount | Date |
|---|---|---|---|---|
| 1 |  Easy Aerial Inc. United States | Series b | $20.0M | today |
| 2 |  KymaThera United States | Series b | $80.0M | today |
| 3 |
